PCP
RETA

Proficio Capital Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Proficio Capital Partners’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-107
Closed -$10K – 1689
2019
Q2 		$10K Buy
107
+39
+57% +$3.37K ﹤0.01% 950
2019
Q1 		$6K Buy
+68
New +$5.64K ﹤0.01% 1082

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Proficio Capital Partners's RETA Position: Q3 2019 in Review

Proficio Capital Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2019, closing a stake of 107 shares — an estimated $10K sold.

Proficio Capital Partners first reported a position in RETA in Q1 2019 and held it in 2 quarters. The position peaked at $10K in Q2 2019. 164 funds tracked by Wall St. Rank hold RETA as of Q3 2019.

  • Proficio Capital Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 107 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2019, an estimated $10K.
  • Proficio Capital Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10K in Q2 2019.
  • 164 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.